273 related articles for article (PubMed ID: 34083233)
21. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
23. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
[TBL] [Abstract][Full Text] [Related]
24. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
[No Abstract] [Full Text] [Related]
26. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
[TBL] [Abstract][Full Text] [Related]
27. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
29. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
Lee H; Sha D; Foster NR; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
Ann Oncol; 2020 Apr; 31(4):487-494. PubMed ID: 32165096
[TBL] [Abstract][Full Text] [Related]
30. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.
Sinicrope FA; Chakrabarti S; Laurent-Puig P; Huebner L; Smyrk TC; Tabernero J; Mini E; Goldberg RM; Zaanan A; Folprecht G; Van Laethem JL; Le Malicot K; Shi Q; Alberts SR; Taieb J
Eur J Cancer; 2021 Feb; 144():101-112. PubMed ID: 33341444
[TBL] [Abstract][Full Text] [Related]
31. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma.
Bachet JB; Blons H; Hammel P; Hariry IE; Portales F; Mineur L; Metges JP; Mulot C; Bourreau C; Cain J; Cros J; Laurent-Puig P
Clin Cancer Res; 2020 Oct; 26(19):5208-5216. PubMed ID: 32605910
[TBL] [Abstract][Full Text] [Related]
32. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C).
Slater S; Bryant A; Chen HC; Begum R; Rana I; Aresu M; Peckitt C; Zhitkov O; Lazaro-Alcausi R; Borja V; Powell R; Lowery D; Hubank M; Rich T; Anandappa G; Chau I; Starling N; Cunningham D
BMC Cancer; 2023 Mar; 23(1):257. PubMed ID: 36941575
[TBL] [Abstract][Full Text] [Related]
33. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P
Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226
[TBL] [Abstract][Full Text] [Related]
34. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
[TBL] [Abstract][Full Text] [Related]
35. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
Tie J; Wang Y; Tomasetti C; Li L; Springer S; Kinde I; Silliman N; Tacey M; Wong HL; Christie M; Kosmider S; Skinner I; Wong R; Steel M; Tran B; Desai J; Jones I; Haydon A; Hayes T; Price TJ; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Sci Transl Med; 2016 Jul; 8(346):346ra92. PubMed ID: 27384348
[TBL] [Abstract][Full Text] [Related]
36. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
37. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
38. Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey.
Ouali K; Turpin A; Neuzillet C; Rousseau B; Garcia-Larnicol ML; Tournigand C; Samalin E; Taieb J; André T; Cohen R
Clin Colorectal Cancer; 2021 Mar; 20(1):79-83.e4. PubMed ID: 33281064
[TBL] [Abstract][Full Text] [Related]
39. HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers.
Veyer D; Wack M; Mandavit M; Garrigou S; Hans S; Bonfils P; Tartour E; Bélec L; Wang-Renault SF; Laurent-Puig P; Mirghani H; Rance B; Taly V; Badoual C; Péré H
Int J Cancer; 2020 Aug; 147(4):1222-1227. PubMed ID: 31756275
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
